Vertex Pharmaceuticals (VRTX) EVP Biller disposes and sells shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Vertex Pharmaceuticals executive Jonathan Biller reported two stock transactions. On February 13, 2026, he disposed of 2,993 shares of common stock at $487.76 per share to cover tax obligations and sold 988 shares in an open-market trade at $499.00 per share. After these transactions, he directly owned 16,838 shares of Vertex common stock. The filing notes the sale was made under a company-approved Rule 10b5-1 trading plan entered into on February 24, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 988 shares ($493,012)
Net Sell
2 txns
Insider
Biller Jonathan
Role
EVP and Chief Legal Officer
Sold
988 shs ($493K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 2,993 | $487.76 | $1.46M |
| Sale | Common Stock | 988 | $499.00 | $493K |
Holdings After Transaction:
Common Stock — 17,826 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transactions did Jonathan Biller report for VRTX?
Jonathan Biller reported a tax-related share disposition and an open-market sale of Vertex (VRTX) common stock. He disposed of 2,993 shares at $487.76 for tax withholding and sold 988 shares at $499.00 per share on February 13, 2026.
Was Jonathan Biller’s VRTX stock sale under a Rule 10b5-1 plan?
Yes, the filing states the transaction was made under a company-approved Rule 10b5-1 trading plan. The plan was entered into on February 24, 2025, providing a pre-arranged framework for selling Vertex (VRTX) shares according to predetermined instructions.
What does the tax-withholding disposition in the VRTX Form 4 mean?
The tax-withholding disposition reflects 2,993 shares of Vertex (VRTX) stock used to satisfy tax liabilities. According to the filing, these shares were valued at $487.76 each and were delivered on February 13, 2026, rather than being sold in an open-market trade.